Discovery to Commercialisation in Rare Diseases

Hosted by J A Kemp at our Farringdon offices, this Genesis Fringe event will look at the role of real-world evidence (RWE) in the drug discovery and commercialisation pathway.

Used effectively, leveraging RWE can enhance the discovery of new disease targets and biomarkers; instigate innovation in clinical trial design and where assets are protected to attract investment, aid commercialisation and hence innovative treatments reaching patients. The speakers at this session will discuss how some of these challenges are being addressed, using the field of rare diseases as an exemplar for lessons applicable in all areas.

Agenda:

15.00 – Registration & Networking
15.30 – Welcome
15.35 - Accessing and utilising rare disease patient data to enable R&D, Ron Jortner, CEO, Aspire Biosciences
15.50 - Standardisation of data collection and sharing to deliver useful RWE to inform clinical trial design, Femida Gwadry-Sridhar, CEO, Pulse Infoframe
16.05 - Clinical Trial Regulation and Transparency Rules - protecting clinical trial-related IP, Ravi Srinivasan, J A Kemp
16.20  - Leveraging RWE in new product commercialisation, Julie Adrian, CEO, Alverium Health
16.35 – Open Q&A with the speakers
17.00 – Networking over drinks & canapes
18.00 – Close

Registration:

This event is free to attend, invite-only and is particularly aimed at attendees from:

• Life Science R&D companies
• TechBio companies
• Tech Transfer Offices/Academia
• Investors
• CRO/CDMO companies

To request an invitation, please email Tony Jones at One Nucleus.